Op werkdagen voor 23:00 besteld, morgen in huis Gratis verzending vanaf €20
, ,

EU Competition Law and Pharmaceuticals

Gebonden Engels 2022 9781802204407
Verwachte levertijd ongeveer 8 werkdagen

Samenvatting

This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.

The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels – in the context of current issues and future trends, including those related to COVID-19 – and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.

Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.

Specificaties

ISBN13:9781802204407
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:324
Druk:1
Verschijningsdatum:15-11-2022
Hoofdrubriek:Juridisch
ISSN:

Lezersrecensies

Wees de eerste die een lezersrecensie schrijft!

Geef uw waardering

Zeer goed Goed Voldoende Matig Slecht

Over Marcel Canoy

De econoom dr. MARCEL CANOY (1963) is distinguished lecturer aan de Erasmus School of Accounting and Assurance en is adviseur bij de Autoriteit Consument en Markt. Hij publiceert geregeld in bladen als NRC Handelsblad en Het Financieele Dagblad, waarin hij een column had. Daarvoor was hij onder meer hoogleraar in Tilburg en werkte hij in de denktank van voormalig Europese Commissievoorzitter Barroso.

Andere boeken door Marcel Canoy

Over Jotte Mulder

Jotte Mulder is an Assistant Professor at the Europa Institute, at the University of Utrecht.

Andere boeken door Jotte Mulder

Inhoudsopgave

Foreword xiv

PART I INTRODUCTION, LEGAL AND
ECONOMIC CONTEXT
1 Introduction 2
Marcel Canoy, Jotte Mulder and Wolf Sauter
2 Excessive pricing doctrine in the pharmaceutical sector: the space for reform 16
Frederick M Abbott
3 Evergreening exclusive rights in pharmaceutical products: the case of SPCs, paediatric extensions and orphan drugs 33
Frantzeska Papadopoulou
4 The economics of patents and innovation in pharma 48
Marcel Canoy and Matthijs Versteegh

PART II THE COMPETITION CASES
SECTION IIA PAY FOR DELAY AND PATENT STRATEGIES
5 Settlement agreements acknowledging patent validity in the United Kingdom 62
Okeoghene Odudu
6 Anticompetitive pharmaceutical patent settlements: the EU cases on pay-for-delay 79
Jotte Mulder and Wolf Sauter

SECTION IIB EXCESSIVE PRICING
7 The Aspen case of the Italian Competition Authority 98
Claudia Desogus
8 Unfair pricing: policy considerations and recent experience in the pharmaceutical sector 113
Andrew Groves and Lourenço Ventura
9 Temporary dominance and excessive pharmaceutical pricing – CD Pharma (Denmark) 124
Behrang Kianzad
10 Excessive pricing for pharmaceuticals in the Netherlands: the Leadiant case 138
Freek Bruggert and Clara Ceulemans
11 The EU Aspen decision: the European Commission’s first excessive pricing decision in the pharmaceutical market 151
Harald Mische

SECTION IIC DISPARAGEMENT AND MISLEADING
INFORMATION
12 Disparagement: the European Union and France 175
Adrien Giraud, Juliette Raffaitin and Constance Dobelmann
13 The dissemination of misleading information in the pharmaceutical market: the Italian experience 199
Margherita Colangelo

SECTION IID MERGERS AND PARALLEL TRADE
14 EU merger control in the pharmaceutical sector: an overview 213
Jan Truijens Martinez
15 Taking stock of the single market imperative in the Court’s case law on parallel trade in pharmaceuticals: are matters as settled as they seem? 229
Jotte Mulder

PART III FUTURE DIRECTIONS
16 Towards responsive enforcement of EU antitrust in pharmaceuticals 248
Wolf Sauter
17 Excessive pricing in pharmaceuticals: perspectives from EU antitrust and regulation 264
Giorgio Monti and Leigh Hancher
18 Tackling grand challenges with competition law: lessons from the pandemic 281
Ioannis Lianos, Timo Minssen and Christy Kollmar

Index

Managementboek Top 100

Rubrieken

Populaire producten

    Personen

      Trefwoorden

        EU Competition Law and Pharmaceuticals